

**ASX RELEASE****Volpara Quarterly Results and Investor Webinar Notification**

Wellington, NZ, 12 July 2023: [Volpara Health Technologies](#) (ASX: VHT), a global leader in breast cancer detection software, will be hosting an investor webinar on **Friday 21<sup>st</sup> July 2023** at 9:00am AEST (Sydney/Melbourne), 11:00am NZST (Auckland/Wellington) to update shareholders on its Q1 FY24 financial results.

The call will be hosted by Teri Thomas, CEO and Managing Director, Craig Hadfield, Chief Financial Officer and Jill Spear, Executive Vice President of Sales and Marketing

**Webinar details**

**Date:** Friday 21<sup>st</sup> July 2023  
**Time:** 9:00am AEST (Sydney/Melbourne), 11:00am NZST (Auckland/Wellington)  
**To register:** [https://us02web.zoom.us/webinar/register/WN\\_yauLLvreR4WkL9NqdHda6g](https://us02web.zoom.us/webinar/register/WN_yauLLvreR4WkL9NqdHda6g)  
**Dial in details:** Will be provided to you upon registration

Participants will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen or can submit them in advance to [hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com).

**Authorisation & Additional Information**

This announcement was authorised by the Chief Executive Officer and Managing Director of Volpara Health Technologies Limited.

**ENDS**

**For further information, please contact:**

**Corporate Enquiries**

Teri Thomas, CEO & MD  
Volpara Health Technologies  
[Teri.thomas@volparahealth.com](mailto:Teri.thomas@volparahealth.com)  
t: +64 4 499 6029

**Investor Relations**

Hannah Howlett  
WE Communications  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)  
t: +61 4 5064 8064

**Media Enquiries**

Trevor Chappell  
WE Communications  
[tchappell@we-worldwide.com](mailto:tchappell@we-worldwide.com)  
t: +61 4 407 933 437

## **About Volpara Health Technologies Limited (ASX: VHT)**

Volpara Health Technologies makes software to save families from cancer. We help leading healthcare providers have a positive impact on communities around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions.

Our focus on customer value means that our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com).